Ropes & Gray represented CAMP4 Therapeutics in a $100 million Series B financing. CAMP4 is pioneering a novel class of RNA-based therapies designed to dial up the output of genes to treat genetic diseases. The company will use the funds to advance its lead programs into the clinic, with an initial focus on a severe form of epilepsy and life-threatening liver diseases.
The financing was announced on July 20. Enavate Sciences, a portfolio company created by Patient Square Capital, led the funding round.
The Ropes & Gray team was led by life sciences partner Marc Rubenstein and associates Joe Muller and Austin Bohn.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.